HMGB1 and myelodysplastic syndrome: These results may represent a new approach to promote cell death in MDS and alter the immune responses associated with the disease, paving the way for new therapeutic strategies. In addition, the potential of HMGB1 as a therapeutic target in myelodysplastic syndrome offers a new perspective for the management of this complex condition